Effects of alemtuzumab injection (multiple sclerosis): A Synthesis of Findings from 5 Studies

  1. Home
  2. Effects of alemtuzumab injection (multiple sclerosis)
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of alemtuzumab injection (multiple sclerosis): A Synthesis of Findings from 5 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of alemtuzumab injection (multiple sclerosis): A Synthesis of Findings from 5 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Aliskiren, a direct renin inhibitor, has been shown to have no clinically relevant effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. 1 This means that aliskiren does not significantly alter how acenocoumarol is absorbed, distributed, metabolized, or eliminated from the body, and it does not affect the anticoagulant effect of acenocoumarol. However, aliskiren may have a renoprotective effect, particularly in reducing albuminuria and proteinuria. 3 While aliskiren is widely used to treat high blood pressure, its effect on major cardiovascular outcomes remains debatable. 2 Additionally, aliskiren has been found to increase the risk of hyperkalemia and renal impairment in patients with diabetes and cardiovascular disease or risk factors. 4

Benefits and Risks

Benefits Summary

Aliskiren may have a renoprotective effect, particularly in reducing albuminuria and proteinuria. 3 Aliskiren is widely used to treat high blood pressure and may have other beneficial effects, although its effect on major cardiovascular outcomes remains debatable. 2

Risks Summary

Aliskiren has been found to increase the risk of hyperkalemia and renal impairment in patients with diabetes and cardiovascular disease or risk factors. 4

Comparison between studies

Similarities between studies

Multiple studies show that aliskiren is a commonly used treatment for high blood pressure.

Differences between studies

Studies have shown different results regarding the side effect profile of aliskiren, particularly in relation to hyperkalemia and renal impairment in patients with diabetes and cardiovascular disease or risk factors. 4

Consistency and contradictions in results

The research results regarding aliskiren's effectiveness in treating high blood pressure are generally consistent, with some studies showing potential renoprotective effects. However, the findings on its side effect profile are inconsistent and more research is needed, particularly on its use in patients with diabetes and cardiovascular disease or risk factors.

Implications for real-life applications

Aliskiren is a common treatment for high blood pressure, and while it is generally safe and effective, there are potential risks such as hyperkalemia and renal impairment, especially in patients with diabetes and cardiovascular disease or risk factors. Doctors should consider these risks and benefits when prescribing aliskiren to patients.

Limitations of current research

More research is needed on the long-term effects and safety of aliskiren, particularly in relation to patients with diabetes and cardiovascular disease or risk factors.

Future research directions

Further research is needed on the long-term effects and safety of aliskiren, particularly its impact on patients with diabetes and cardiovascular disease or risk factors.

Conclusion

Aliskiren is a widely used drug for treating high blood pressure. While it has been shown to be safe and effective, potential risks, including hyperkalemia and renal impairment, especially in patients with diabetes and cardiovascular disease or risk factors, need careful consideration. Further research on the long-term effects and safety of aliskiren, particularly on its use in specific patient groups, is necessary.

Literature analysis of 5 papers
Positive Content
4
Neutral Content
0
Negative Content
1
Article Type
1
4
3
3
5
1.

Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.

Author: HuangH-L A, VaidyanathanS, YehC-M, BizotM-N, DieterichH A, DoleW P, HowardD

Aliskiren, a direct renin inhibitor for hypertension, had no clinically relevant effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.

Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials.

Author: ZhangJing-Tao, ChenKe-Ping, GuanTing, ZhangShu

hypertension treatment

This meta-analysis evaluated the effects of aliskiren therapy on major cardiovascular outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

3.

Renoprotection by Direct Renin Inhibition: A Systematic Review and Meta- Analysis.

Author: LouvisNikolaos, CoulsonJames

Reduced albuminuria
Renoprotection

This study assessed the renoprotective effects of aliskiren, a direct renin inhibitor. The authors found that aliskiren decreased albuminuria and proteinuria, suggesting that it may confer renoprotection by this mechanism. However, aliskiren did not appear to significantly change serum creatinine concentration (sCr) or estimated glomerular filtration rate (eGFR).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

4.

Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.

Author: ZhengSean L, RoddickAlistair J, AyisSalma

Hyperkalemia
Renal impairment

This meta-analysis investigated the efficacy and safety of aliskiren in patients with diabetes and increased cardiovascular risk or established cardiovascular disease. Aliskiren had no effect on all-cause mortality or combined cardiovascular mortality or heart failure hospitalization. However, patients receiving aliskiren had a greater risk of developing hyperkalemia and renal impairment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

5.

Clinical efficacy, safety and tolerability of aliskiren monotherapy: a protocol for an umbrella review.

Author: ZhaoQiyuan, ShenJiantong, LuJingya, LiFan, JiangQi, WangYuanyuan

Blood pressure reduction
Safety concerns

This paper systematically summarizes the published studies on the clinical efficacy and side effects of aliskiren monotherapy. Aliskiren, a renin-angiotensin-aldosterone system inhibitor, has been recognized for its role in lowering blood pressure. However, its safety and tolerability remain controversial.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.